C2N strategic collaboration

Advancing Alzheimer’s disease testing

Alzheimer’s disease affects millions of individuals and is projected to reach 13.8 million cases in the U.S. by 2060. With FDA-approved treatments available to slow the progression of the disease, early and accurate diagnosis is key to helping patients prepare for the future. Mayo Clinic Laboratories has entered a strategic collaboration with C2N Diagnostics to expand access to noninvasive, blood-based biomarker testing for Alzheimer’s disease. This collaboration introduces Precivity™ plasma biomarker tests, which provide critical insights into the presence of amyloid pathology and help clinicians identify patients at risk. Together, we aim to improve early detection and patient care.

Innovative blood-based testing

Precivity™ tests and Mayo Clinic Laboratories’ p-Tau217 assay offer noninvasive, highly accurate tools for detecting amyloid pathology. These tests eliminate the need for lumbar punctures and provide results within days, enabling timely diagnosis and intervention.

Collaborative expertise

Our strategic collaboration combines Mayo Clinic Laboratories’ leadership in clinical diagnostics with C2N’s pioneering research in neurodegenerative biomarkers. Together, we deliver solutions that empower healthcare providers with actionable insights for patient care.

Patient-centered impact

Early detection opens a window of opportunity for disease management. By expanding access to advanced Alzheimer’s testing, we help clinicians make informed decisions that improve outcomes and quality of life for patients facing cognitive impairment.

“Now that we have disease-modifying therapies available, biomarker testing for Alzheimer’s disease will become an essential component of clinical evaluations.”

Alicia Algeciras-Schimnich, Ph.D., Co-Director of the Clinical Immunoassay Laboratory at Mayo Clinic

The latest

Breakthroughs and Trends That Defined Lab Medicine in 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent news updates and key advancements shaping the industry in 2025.

Learn more

Forging Collaborations That Deliver Better Outcomes

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories. Together, they discuss recent news about virus activity and explore the value of collaboration in shaping innovative diagnostic strategies.

Top 5 Mayo Clinic Laboratories advancements in 2024

Five of the most significant advancements from Mayo Clinic Laboratories in 2024 to enhance diagnostics and patient care globally.

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

Resources

Learn more Plasma biomarker testing at Mayo Clinic Laboratories